Jeffrey R Curtis1, Leslie R Harrold2, Maryam M Asgari3, Atul Deodhar4, Craig Salman5, Joel M Gelfand6, Jashin J Wu7, Lisa J Herrinton8. 1. Professor of Medicine in the Department of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham. jcurtis@uab.edu. 2. Associate Professor at the Meyers Primary Care Institute and Fallon Clinic at the University of Massachusetts Medical School. leslie.harrold@umassmed.edu. 3. Research Scientist for the Division of Research in Oakland, CA. masgari@partners.org. 4. Professor of Medicine at Oregon Health and Science University in Portland. deodhara@ohsu.edu. 5. Data Analyst at the American Academy of Ophthalmology in San Francisco, CA. andyc298@yahoo.com. 6. Dermatologist at the University of Pennsylvania in Philadelphia. joel.gelfand@uphs.upenn.edu. 7. Director of Dermatology Research for the Department of Dermatology at the Los Angeles Medical Center in CA. jashin.j.wu@kp.org. 8. Research Scientist for the Division of Research in Oakland, CA. lisa.herrinton@kp.org.
Abstract
INTRODUCTION: Few studies have assessed the prevalence and features of axial spondyloarthritis (axSpA) and ankylosing spondylitis in diverse, population-based, community settings. OBJECTIVES: We used computerized diagnoses to estimate the prevalence of axSpA and ankylosing spondylitis in Kaiser Permanente Northern California (KPNC). METHODS: We identified persons aged 18 years or older with 1 or more International Classification of Diseases, Ninth Revision (ICD-9) diagnosis Code 720.X (ankylosing spondylitis and other inflammatory spondylopathies) in clinical encounter data from 1996 through 2009 to estimate the prevalence of axSpA and ankylosing spondylitis. We reviewed medical records to confirm the diagnosis in a random sample and estimated the positive predictive value of computerized data to identify confirmed cases using various case definitions. RESULTS: In the computerized data, 5568 adults had diagnostic codes indicating axSpA. On the basis of our case-finding approach using a single physician diagnosis code for ICD-9 720.X, the point prevalence of these conditions, standardized to the 2000 US Census, was 2.26 per 1000 persons for axSpA and 1.07 per 1000 for ankylosing spondylitis. Less than half of suspected cases saw a rheumatologist. The most specific algorithm for confirmed ankylosing spondylitis required 2 or more computerized diagnoses assigned by a rheumatologist, with 67% sensitivity (95% confidence interval, 64%-69%) and 81% positive predictive value (95% confidence interval, 79%-83%). CONCLUSIONS: Observed prevalence in the KPNC population, compared with national estimates for axSpA and ankylosing spondylitis, suggests there is substantial underrecognition of these conditions in routine clinical practice. However, use of computerized data is able to identify true cases of ankylosing spondylitis, facilitating population-based research.
INTRODUCTION: Few studies have assessed the prevalence and features of axial spondyloarthritis (axSpA) and ankylosing spondylitis in diverse, population-based, community settings. OBJECTIVES: We used computerized diagnoses to estimate the prevalence of axSpA and ankylosing spondylitis in Kaiser Permanente Northern California (KPNC). METHODS: We identified persons aged 18 years or older with 1 or more International Classification of Diseases, Ninth Revision (ICD-9) diagnosis Code 720.X (ankylosing spondylitis and other inflammatory spondylopathies) in clinical encounter data from 1996 through 2009 to estimate the prevalence of axSpA and ankylosing spondylitis. We reviewed medical records to confirm the diagnosis in a random sample and estimated the positive predictive value of computerized data to identify confirmed cases using various case definitions. RESULTS: In the computerized data, 5568 adults had diagnostic codes indicating axSpA. On the basis of our case-finding approach using a single physician diagnosis code for ICD-9 720.X, the point prevalence of these conditions, standardized to the 2000 US Census, was 2.26 per 1000 persons for axSpA and 1.07 per 1000 for ankylosing spondylitis. Less than half of suspected cases saw a rheumatologist. The most specific algorithm for confirmed ankylosing spondylitis required 2 or more computerized diagnoses assigned by a rheumatologist, with 67% sensitivity (95% confidence interval, 64%-69%) and 81% positive predictive value (95% confidence interval, 79%-83%). CONCLUSIONS: Observed prevalence in the KPNC population, compared with national estimates for axSpA and ankylosing spondylitis, suggests there is substantial underrecognition of these conditions in routine clinical practice. However, use of computerized data is able to identify true cases of ankylosing spondylitis, facilitating population-based research.
Authors: P Trontzas; A Andrianakos; S Miyakis; K Pantelidou; E Vafiadou; V Garantziotou; C Voudouris Journal: Clin Rheumatol Date: 2005-04-29 Impact factor: 2.980
Authors: S Hukuda; M Minami; T Saito; H Mitsui; N Matsui; Y Komatsubara; H Makino; T Shibata; M Shingu; T Sakou; K Shichikawa Journal: J Rheumatol Date: 2001-03 Impact factor: 4.666
Authors: M Rudwaleit; D van der Heijde; R Landewé; N Akkoc; J Brandt; C T Chou; M Dougados; F Huang; J Gu; Y Kirazli; F Van den Bosch; I Olivieri; E Roussou; S Scarpato; I J Sørensen; R Valle-Oñate; U Weber; J Wei; J Sieper Journal: Ann Rheum Dis Date: 2010-11-24 Impact factor: 19.103
Authors: M Rudwaleit; D van der Heijde; R Landewé; J Listing; N Akkoc; J Brandt; J Braun; C T Chou; E Collantes-Estevez; M Dougados; F Huang; J Gu; M A Khan; Y Kirazli; W P Maksymowych; H Mielants; I J Sørensen; S Ozgocmen; E Roussou; R Valle-Oñate; U Weber; J Wei; J Sieper Journal: Ann Rheum Dis Date: 2009-03-17 Impact factor: 19.103
Authors: Maureen Dubreuil; Christine Peloquin; Yuqing Zhang; Hyon K Choi; Robert D Inman; Tuhina Neogi Journal: Pharmacoepidemiol Drug Saf Date: 2016-01-13 Impact factor: 2.890
Authors: Michael D George; Joshua F Baker; Jesse Yenchih Hsu; Qufei Wu; Fenglong Xie; Lang Chen; Huifeng Yun; Jeffrey R Curtis Journal: Arthritis Care Res (Hoboken) Date: 2017-11-02 Impact factor: 4.794
Authors: Maria C Schneeweiss; Seoyoung C Kim; Sebastian Schneeweiss; David Rosmarin; Joseph F Merola Journal: JAMA Dermatol Date: 2020-03-01 Impact factor: 10.282
Authors: Kate L Lapane; Catherine Dubé; Katarina Ferrucci; Sara Khan; Kristine A Kuhn; Esther Yi; Jonathan Kay; Shao-Hsien Liu Journal: BMC Fam Pract Date: 2021-12-20 Impact factor: 2.497
Authors: Ian C Scott; Rebecca Whittle; James Bailey; Helen Twohig; Samantha L Hider; Christian D Mallen; Sara Muller; Kelvin P Jordan Journal: Lancet Reg Health Eur Date: 2022-10-10